Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy

Tristan M. Sissung,Romano Danesi,C. Tyler Kirkland,Caitlin E. Baum,Sandra B. Ockers,Erica V. Stein,David Venzon,Douglas K. Price,William D. Figg

Estrogen Receptor α and Aromatase Polymorphisms Affect Risk, Prognosis, and Therapeutic Outcome in Men with Castration-Resistant Prostate Cancer Treated with Docetaxel-Based Therapy

2011

Tristan M. Sissung
Romano Danesi
C. Tyler Kirkland
Caitlin E. Baum
Sandra B. Ockers
Erica V. Stein
David Venzon
Douglas K. Price
William D. Figg

ERα and CYP19 polymorphisms affect the therapeutic outcome of docetaxel in patients with castrationresistant prostate cancer (CRPC) and are associated with CRPC risk.

Keywords:

Aromatase
Orchiectomy
Endocrinology
Pharmacogenetics
Prostate cancer
Estrogen
Estrogen receptor
Internal medicine
Medicine
Estrogen receptor alpha
Docetaxel
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations